Tuberculosis Medications Program - Minnesota Dept. of Health

Tuberculosis Medications Program

As of July 15, 2019, there are new eligibility requirements for accessing latent TB infection (LTBI) medications through MDH due to budget constraints. See TB Medications Program Eligibility for more information.

The Minnesota Department of Health (MDH) Tuberculosis (TB) Prevention and Control Program's TB Medications Program serves to eliminate financial barriers to medication for the treatment of latent TB infection (LTBI) or active TB disease for state residents. When possible, the program coordinates with a contracted pharmacy to bill individuals' prescription insurance while covering related co-pays, so that TB medications are always at no cost to the patients.

On this page:
Medications for latent TB infection
Medication for active TB disease
Letters

CDC Rifamycin Issues - September 11, 2020
CDC announced a Dear Colleague Letter: Update on Rifamycin Issues regarding the FDA statements related to mitigating shortages of rifampin and rifapentine. The CDC has provided interim guidance to continue using these drugs in the treatment of tuberculosis (TB) after nitrosamine-class impurities were detected through recently adopted regulatory standards. Please review the CDC publication Dear Colleague Letter: Rifampin Availability from August 19, 2020 for more information.

CDC Rifapentine Alert - June 18, 2020
CDC announced a Dear Colleagues Letter: Reported Rifapentine Impurity about the LTBI treatment drug used in the 3HP regimen. The FDA and Sanofi are investigating the issue. Providers can consider alternative regimens for patients taking Rifapentine. New 3HP regimens should not begin until the impurity issue has been resolved. Updates to this situation are ongoing.

Medication for latent TB infection

  1. Review TB Medications Program Eligibility to verify the patient is eligible for medication from the Minnesota Department of Health at no-cost to the patient.

  2. Review CDC: Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (PDF) to determine the most effective treatment for your patient. CDC and MDH promote the use of shorter regimens to increase patient completion rates. The regimens of 4R or 3HR can be advantageous over 3HP if your patient requires assistance with adherence or is adverse to the need to take numerous pills simultaneously. 4R and 3HR are lower cost regimens as well. The following document provides guidance to treatment completion criteria.
  3. The provider should complete and submit the request form to MDH using the following online survey:
  4. Through our contracted pharmacy, MDH ships the patient's first month supply of LTBI medication within 5 – 7 business days, to the designated health care professional, licensed to administer medications.

  5. Complete the form that was included with the first shipment.
    • LTBI Medication Start Date Verification Form (PDF)
      Fax completed form to: 1-800-296-0993
    • Upon receiving this verification, MDH will ship monthly refills until the order is filled.
    • If treatment is discontinued for any reason or if the patient is lost to follow-up, please contact MDH at 651-201-5414 ASAP to stop shipments.

  6. The health care professional that receives medication shipments is responsible for monitoring the patient for adverse drug reactions and adherence to the regimen. The timing and type of monitoring activities should be done according to CDC guidelines for each regimen.

LTBI medication prescription templates

More about LTBI medications

  • TB Basics
    Fact sheets for patients, including fact sheets on LTBI treatment and specific LTBI medications.

Medication for active TB disease

  1. To request medications for treatment of active TB disease, the provider should contact the MDH TB Nurse Case Manager at 651-201-5414 or 1-877-676-5414.

  2. The provider will be asked to provide pertinent clinical and demographic information, a copy of the prescription(s), patient prescription insurance information.
    Request for Active Tuberculosis Medications (Presumed/Confirmed) (PDF)

  3. Medications will be sent monthly to the designated clinic, local public health agency, or other provider licensed to administer medications.

  4. If a patient being treated for active TB disease stops therapy, fails to pick up medications, or if treatment is discontinued, please contact the MDH TB Nurse Case Manager immediately.

Letters

Updated Tuesday, 01-Jun-2021 11:29:42 CDT